logo
  • Provider Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Side Effect Search
    • Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • BRAF Q&A
    • ctDNA Testing Handout
    • Videos
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Provider Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Side Effect Search
    • Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • BRAF Q&A
    • ctDNA Testing Handout
    • Videos
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK

The Melanoma Hub – Home › Forums

    • Immunotherapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 6
    • 20
    • Reply To: Adjuvant Immunotherapy in stage IIIA patients

      May 5, 2018 at 8:59 pm

      Rajni Kannan

    • Dosing and administration
    • 4
    • 28
    • Reply To: Nivolumab dilution

      November 18, 2018 at 9:24 am

      Kathleen Madden

    • Side-effect management
    • 23
    • 98
    • Reply To: Esophagitis

      February 18, 2019 at 7:56 am

      Suzanne McGettigan

    • Reimbursement
    • 3
    • 21
    • Reply To: Nivolumab dosing and Medicare

      July 23, 2018 at 4:02 pm

      Rajni Kannan

    • Other
    • 12
    • 49
    • Immunotherapy in Hepatitis B carriers

      February 25, 2019 at 4:33 pm

      Suzanne McGettigan

  •  

    • Targeted therapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 1
    • 2
    • Reply To: Targeted therapies for adjuvant therapy

      November 3, 2017 at 2:07 am

      Virginia Seery

    • Dosing and administration
    • 2
    • 18
    • Reply To: New BRAF/MEK inhibitors coming to market

      October 8, 2018 at 10:07 am

      Suzanne McGettigan

    • Side-effect management
    • 2
    • 9
    • Reply To: Fevers

      October 28, 2018 at 9:00 am

      Kathleen Madden

    • Reimbursement
    • 0
    • 0
    • December 8, 2017 at 4:58 pm

      LisaTushla

    • Other
    • 7
    • 26
    • Reply To: Variants to mutations; fusions and

      June 25, 2018 at 8:58 am

      Suzanne McGettigan

  •  

    • Intralesional immunotherapy
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 0
    • 0
    • No Topics

    • Dosing and administration
    • 2
    • 8
    • Reply To: Premedication

      April 29, 2018 at 2:54 pm

      Kathleen Madden

    • Infectious Precautions
    • 2
    • 9
    • Reply To: TVEC infection control practices

      February 11, 2018 at 12:00 am

      Krista Rubin

    • Side-effect management
    • 1
    • 8
    • Reply To: Ocular herpes

      January 5, 2018 at 2:54 am

      Virginia Seery

    • Reimbursement
    • 1
    • 1
    • December 8, 2017 at 4:58 pm

    • Other
    • 0
    • 0
    • No Topics

  •  

    • Living With Melanoma
    • Topics
    • Posts
    • Last Post
    • Alternative/complementary therapies
    • 1
    • 6
    • Reply To: Herbal medications

      June 22, 2018 at 7:29 pm

      Mollie Reed

    • Fertility
    • 1
    • 10
    • Reply To: Family planning

      March 29, 2018 at 9:31 pm

      Mollie Reed

    • Nutrition
    • 2
    • 5
    • Reply To: Sugar and melanoma

      January 31, 2018 at 8:43 pm

      Lisa Kottschade

    • Coordination of care
    • 2
    • 14
    • Reply To: Survivorship plans

      March 29, 2018 at 9:39 pm

      Mollie Reed

    • Other
    • 3
    • 6
    • Reply To: Vaccines

      February 1, 2018 at 3:46 am

      Krista Rubin

  •  

Login

Log In
Register Lost Password

Latest Activity

  • Immunotherapy in Hepatitis B carriers
    topic by Suzanne McGettigan
    February 25
    in Other
  • Esophagitis
    reply by Suzanne McGettigan
    February 18
    in Side-effect management
  • mucositis & mouth sores from Nivo
    reply by Kathleen Madden
    January 27
    in Side-effect management
  • Immunotherapy and Solid organ transplant
    reply by Krista Rubin
    January 23
    in Other
  • Nivolumab dilution
    reply by Kathleen Madden
    November 18
    in Dosing and administration
© 2024 The Melanoma Hub, Terranova Medica, LLC, and Integrita Foundation, LLC. All rights reserved.
  • About
  • Terms
  • Privacy
  • Contact